52 North Health Ltd. raised $6 million in financing to bring its oncology products to the market including the Neutrocheck, a point-of-care device and app which monitors cancer patients at home at risk of developing neutropenic sepsis.
The recent $73 million raised by Cradle NV in a series B financing round will allow the company to build out its operations and improve its artificial intelligence-powered protein engineering platform.
RSS
